422 related articles for article (PubMed ID: 16632328)
1. The role of sodium channels in chronic inflammatory and neuropathic pain.
Amir R; Argoff CE; Bennett GJ; Cummins TR; Durieux ME; Gerner P; Gold MS; Porreca F; Strichartz GR
J Pain; 2006 May; 7(5 Suppl 3):S1-29. PubMed ID: 16632328
[TBL] [Abstract][Full Text] [Related]
2. Sodium channel blockade may contribute to the analgesic efficacy of antidepressants.
Dick IE; Brochu RM; Purohit Y; Kaczorowski GJ; Martin WJ; Priest BT
J Pain; 2007 Apr; 8(4):315-24. PubMed ID: 17175203
[TBL] [Abstract][Full Text] [Related]
3. Voltage-gated sodium channels and hyperalgesia.
Lai J; Porreca F; Hunter JC; Gold MS
Annu Rev Pharmacol Toxicol; 2004; 44():371-97. PubMed ID: 14744251
[TBL] [Abstract][Full Text] [Related]
4. The role of tetrodotoxin-resistant sodium channels in pain states: are they the next target for analgesic drugs?
Silos-Santiago I
Curr Opin Investig Drugs; 2008 Jan; 9(1):83-9. PubMed ID: 18183535
[TBL] [Abstract][Full Text] [Related]
5. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine.
Sheets PL; Heers C; Stoehr T; Cummins TR
J Pharmacol Exp Ther; 2008 Jul; 326(1):89-99. PubMed ID: 18378801
[TBL] [Abstract][Full Text] [Related]
6. Translating basic research on sodium channels in human neuropathic pain.
Attal N; Bouhassira D
J Pain; 2006 Jan; 7(1 Suppl 1):S31-7. PubMed ID: 16426999
[TBL] [Abstract][Full Text] [Related]
7. Voltage-gated sodium channels: therapeutic targets for pain.
Dib-Hajj SD; Black JA; Waxman SG
Pain Med; 2009 Oct; 10(7):1260-9. PubMed ID: 19818036
[TBL] [Abstract][Full Text] [Related]
8. Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
Cummins TR; Rush AM
Expert Rev Neurother; 2007 Nov; 7(11):1597-612. PubMed ID: 17997706
[TBL] [Abstract][Full Text] [Related]
9. The role of sodium channels in neuropathic pain.
Rogers M; Tang L; Madge DJ; Stevens EB
Semin Cell Dev Biol; 2006 Oct; 17(5):571-81. PubMed ID: 17123847
[TBL] [Abstract][Full Text] [Related]
10. The pharmacology of voltage-gated sodium channels in sensory neurones.
Docherty RJ; Farmer CE
Handb Exp Pharmacol; 2009; (194):519-61. PubMed ID: 19655117
[TBL] [Abstract][Full Text] [Related]
11. Voltage-gated sodium channels and pain pathways.
Wood JN; Boorman JP; Okuse K; Baker MD
J Neurobiol; 2004 Oct; 61(1):55-71. PubMed ID: 15362153
[TBL] [Abstract][Full Text] [Related]
12. Sodium channel blockers in neuropathic pain.
Kalso E
Curr Pharm Des; 2005; 11(23):3005-11. PubMed ID: 16178759
[TBL] [Abstract][Full Text] [Related]
13. Small molecules targeting sodium and calcium channels for neuropathic pain.
Bear B; Asgian J; Termin A; Zimmermann N
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):543-61. PubMed ID: 19562650
[TBL] [Abstract][Full Text] [Related]
14. Use-dependent block by lidocaine but not amitriptyline is more pronounced in tetrodotoxin (TTX)-Resistant Nav1.8 than in TTX-sensitive Na+ channels.
Leffler A; Reiprich A; Mohapatra DP; Nau C
J Pharmacol Exp Ther; 2007 Jan; 320(1):354-64. PubMed ID: 17005919
[TBL] [Abstract][Full Text] [Related]
15. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.
Kort ME; Drizin I; Gregg RJ; Scanio MJ; Shi L; Gross MF; Atkinson RN; Johnson MS; Pacofsky GJ; Thomas JB; Carroll WA; Krambis MJ; Liu D; Shieh CC; Zhang X; Hernandez G; Mikusa JP; Zhong C; Joshi S; Honore P; Roeloffs R; Marsh KC; Murray BP; Liu J; Werness S; Faltynek CR; Krafte DS; Jarvis MF; Chapman ML; Marron BE
J Med Chem; 2008 Feb; 51(3):407-16. PubMed ID: 18176998
[TBL] [Abstract][Full Text] [Related]
16. Future potential and status of selective sodium channel blockers for the treatment of pain.
Priest BT
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):682-92. PubMed ID: 19736626
[TBL] [Abstract][Full Text] [Related]
17. [Pathophysiology of neuropathic pain: Na⁺ channel and hyperexcitability of primary afferents].
Misawa S
Brain Nerve; 2012 Nov; 64(11):1249-53. PubMed ID: 23131735
[TBL] [Abstract][Full Text] [Related]
18. Local anesthetic-like inhibition of voltage-gated Na(+) channels by the partial μ-opioid receptor agonist buprenorphine.
Leffler A; Frank G; Kistner K; Niedermirtl F; Koppert W; Reeh PW; Nau C
Anesthesiology; 2012 Jun; 116(6):1335-46. PubMed ID: 22504149
[TBL] [Abstract][Full Text] [Related]
19. Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain.
Gaida W; Klinder K; Arndt K; Weiser T
Neuropharmacology; 2005 Dec; 49(8):1220-7. PubMed ID: 16182323
[TBL] [Abstract][Full Text] [Related]
20. Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites.
Leffler A; Reckzeh J; Nau C
Eur J Pharmacol; 2010 Mar; 630(1-3):19-28. PubMed ID: 20044988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
